glp 1 compounding ban 🚨 FDA Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale of GLP-1 medications like semaglutide and tirzepatide, signaling a major shift in how these FDA issued 25 warning letters

Obesity and gallstone disease often share common risk factors including metabolic syndrome, insulin resistance, and dietary patterns

doi: 10.3389/fmicb.2024.1487641 220 SathitkowitchaiW.SathapondechaP.AngthongP.SrimarutY.MalilaY.NakkongkamW.et al

Direct answer: The latest update is that FDA resolved the tirzepatide injection shortage and ended the main shortage-based compounding grace periods in 2025

Sources Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist (PMC) Application of nutrition interventions with GLP-1 based therapies: a narrative review (PMC) Endocrine Society: Consuming more protein may protect patients taking anti-obesity drug from muscle loss (ENDO 2025) Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists (PMC) MedlinePlus: Fiber MedlinePlus: High-fiber foods Mayo Clinic Health System: Assessing protein needs Mayo Clinic: High-protein snacks Therapeutic Benefits and Dietary Restrictions of Fiber Intake (PMC)